[go: up one dir, main page]

NO20024235L - 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer - Google Patents

5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer

Info

Publication number
NO20024235L
NO20024235L NO20024235A NO20024235A NO20024235L NO 20024235 L NO20024235 L NO 20024235L NO 20024235 A NO20024235 A NO 20024235A NO 20024235 A NO20024235 A NO 20024235A NO 20024235 L NO20024235 L NO 20024235L
Authority
NO
Norway
Prior art keywords
alkylpyrido
tyrosine kinase
kinase inhibitors
pyrimidine
pyrimidine tyrosine
Prior art date
Application number
NO20024235A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024235D0 (no
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20024235D0 publication Critical patent/NO20024235D0/no
Publication of NO20024235L publication Critical patent/NO20024235L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20024235A 2000-03-06 2002-09-05 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer NO20024235L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20024235D0 NO20024235D0 (no) 2002-09-05
NO20024235L true NO20024235L (no) 2002-11-05

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024235A NO20024235L (no) 2000-03-06 2002-09-05 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer

Country Status (36)

Country Link
EP (1) EP1268476A1 (xx)
JP (1) JP2003528101A (xx)
KR (1) KR20020075805A (xx)
CN (1) CN1422268A (xx)
AP (1) AP2002002643A0 (xx)
AR (1) AR034119A1 (xx)
AU (1) AU2001233028A1 (xx)
BG (1) BG107161A (xx)
BR (1) BR0109056A (xx)
CA (1) CA2401368A1 (xx)
CO (1) CO5280200A1 (xx)
CR (1) CR6736A (xx)
CZ (1) CZ20022929A3 (xx)
DZ (1) DZ3308A1 (xx)
EA (1) EA200200802A1 (xx)
EE (1) EE200200506A (xx)
GT (1) GT200100037A (xx)
HN (1) HN2001000040A (xx)
HR (1) HRP20020798A2 (xx)
HU (1) HUP0300136A2 (xx)
IL (1) IL151480A0 (xx)
IS (1) IS6524A (xx)
MA (1) MA26881A1 (xx)
MX (1) MXPA02008535A (xx)
NO (1) NO20024235L (xx)
NZ (1) NZ520962A (xx)
OA (1) OA12227A (xx)
PA (1) PA8513201A1 (xx)
PE (1) PE20011177A1 (xx)
PL (1) PL358271A1 (xx)
SK (1) SK12472002A3 (xx)
SV (1) SV2001000338A (xx)
TN (1) TNSN01036A1 (xx)
WO (1) WO2001070741A1 (xx)
YU (1) YU66502A (xx)
ZA (1) ZA200207110B (xx)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
CZ20032416A3 (cs) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituované pyridopyrimidiny
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
EP1408985A4 (en) * 2001-06-21 2006-03-22 Ariad Pharma Inc NEW PYRIDOPYRIMIDONE AND ITS USES
EA007395B3 (ru) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
AU2003225072A1 (en) 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
SI1685131T1 (sl) 2003-11-13 2007-06-30 Hoffmann La Roche Hidroksialkil-substituirani pirido-7-pirimidin-7-oni
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
PL1940839T3 (pl) * 2005-10-07 2013-12-31 Exelixis Inc Pirydopirymidynonowe inhibitory PI3Kalfa
EP1931670B1 (en) 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AP2710A (en) 2006-09-15 2013-07-30 Pfizer Prod Inc Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
DK2137184T3 (da) * 2007-04-03 2013-07-22 Array Biopharma Inc Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
RU2010101052A (ru) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Производные бициклоанилина
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2012004157A (es) * 2009-10-09 2012-08-03 Afraxis Inc 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
JP5797664B2 (ja) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
DK2600719T3 (da) 2010-08-05 2014-12-15 Univ Temple 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX347040B (es) * 2011-05-17 2017-04-10 Principia Biopharma Inc Inhibidores de tirosina-cinasas.
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
ES2694787T3 (es) * 2013-02-21 2018-12-27 Pfizer Inc. Formas sólidas de un inhibidor selectivo de CDK4/6
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
JP6631616B2 (ja) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
RU2726115C1 (ru) 2016-08-15 2020-07-09 Пфайзер Инк. Пиридопиримидиновые ингибиторы cdk2/4/6
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
SG11202007754UA (en) 2018-02-15 2020-09-29 Nuvation Bio Inc Heterocyclic compounds as kinase inhibitors
CN113166148B (zh) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
JP2024508901A (ja) * 2021-03-08 2024-02-28 曁南大学 ピリドピリミジン系化合物及びその使用
WO2024056091A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
AP2000001964A0 (en) * 1998-05-26 2000-12-31 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.

Also Published As

Publication number Publication date
TNSN01036A1 (en) 2005-11-10
CR6736A (es) 2004-03-10
BR0109056A (pt) 2003-06-03
YU66502A (sh) 2005-09-19
HUP0300136A2 (en) 2003-05-28
JP2003528101A (ja) 2003-09-24
OA12227A (en) 2004-03-18
ZA200207110B (en) 2003-12-04
KR20020075805A (ko) 2002-10-05
AR034119A1 (es) 2004-02-04
IS6524A (is) 2002-08-23
EP1268476A1 (en) 2003-01-02
SK12472002A3 (sk) 2003-04-01
EE200200506A (et) 2004-02-16
HN2001000040A (es) 2001-09-06
AU2001233028A1 (en) 2001-10-03
NZ520962A (en) 2003-09-26
CN1422268A (zh) 2003-06-04
MA26881A1 (fr) 2004-12-20
BG107161A (en) 2003-06-30
SV2001000338A (es) 2001-11-30
CZ20022929A3 (cs) 2003-02-12
CO5280200A1 (es) 2003-05-30
IL151480A0 (en) 2003-04-10
AP2002002643A0 (en) 2002-12-31
HRP20020798A2 (en) 2004-02-29
DZ3308A1 (fr) 2001-09-27
NO20024235D0 (no) 2002-09-05
WO2001070741A1 (en) 2001-09-27
EA200200802A1 (ru) 2003-02-27
PA8513201A1 (es) 2003-06-30
PL358271A1 (en) 2004-08-09
GT200100037A (es) 2002-03-04
CA2401368A1 (en) 2001-09-27
MXPA02008535A (es) 2002-12-13
PE20011177A1 (es) 2001-11-23

Similar Documents

Publication Publication Date Title
NO20024235L (no) 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer
ATE257157T1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen als protein kinasen hemmer
ATE286045T1 (de) Tyrosin kinaseinhibitoren
IS6968A (is) Nýir týrósínkínasa tálmar
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
NO20031852L (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20034929L (no) 4-amino-5-fenyl-7-cyklobutylpyrrol(2,3-D)pyrimidinderivater
PT1200435E (pt) Derivados de purina inibidores tirosina proteina quinase syk
IS6443A (is) Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar
AU2002348394A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (en) Tyrosine kinase inhibitors
ATE231866T1 (de) Pyrazolo(4, 3-d)pyrimidine
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
ATE276260T1 (de) 2-aminoalkyl-thieno(2,3-d)pyrimidine
ATE297927T1 (de) Substituierte 3,4-dihydro-pyrido(1,2-a)pyrimidine
DK1226136T3 (da) Tyrosinkinaseinhibitor
AU2002326760A1 (en) Tyrosine kinase inhibitors
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002326758A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application